Agilent Technologies, Inc. (NYSE:A) Shares Sold by Waterloo Capital L.P.

Waterloo Capital L.P. reduced its position in Agilent Technologies, Inc. (NYSE:A - Free Report) by 76.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,675 shares of the medical research company's stock after selling 5,559 shares during the quarter. Waterloo Capital L.P.'s holdings in Agilent Technologies were worth $225,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Sienna Gestion boosted its stake in Agilent Technologies by 29.8% in the 4th quarter. Sienna Gestion now owns 78,445 shares of the medical research company's stock worth $10,537,000 after purchasing an additional 17,991 shares in the last quarter. Sequoia Financial Advisors LLC raised its holdings in shares of Agilent Technologies by 8.5% in the fourth quarter. Sequoia Financial Advisors LLC now owns 33,898 shares of the medical research company's stock worth $4,554,000 after buying an additional 2,664 shares during the last quarter. S.E.E.D. Planning Group LLC lifted its stake in shares of Agilent Technologies by 12.7% during the fourth quarter. S.E.E.D. Planning Group LLC now owns 42,587 shares of the medical research company's stock worth $5,721,000 after buying an additional 4,805 shares during the period. Commonwealth Equity Services LLC grew its holdings in shares of Agilent Technologies by 9.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 43,862 shares of the medical research company's stock valued at $5,892,000 after buying an additional 3,915 shares during the last quarter. Finally, Daiwa Securities Group Inc. increased its position in shares of Agilent Technologies by 16.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 49,288 shares of the medical research company's stock valued at $6,621,000 after acquiring an additional 6,802 shares during the period.

Remove Ads

Wall Street Analysts Forecast Growth

A has been the subject of a number of research reports. StockNews.com raised Agilent Technologies from a "hold" rating to a "buy" rating in a report on Tuesday, December 24th. Barclays cut their target price on shares of Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating for the company in a report on Thursday. Robert W. Baird lowered their price target on shares of Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating on the stock in a report on Thursday, February 27th. Citigroup lifted their price objective on shares of Agilent Technologies to $165.00 and gave the company a "buy" rating in a report on Thursday, December 19th. Finally, TD Cowen upped their price objective on shares of Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research report on Thursday. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $146.25.

Agilent Technologies Price Performance

A stock traded up $2.71 during trading on Friday, hitting $102.66. The stock had a trading volume of 2,848,584 shares, compared to its average volume of 1,858,598. The company's 50-day moving average price is $123.76 and its two-hundred day moving average price is $133.84. Agilent Technologies, Inc. has a twelve month low of $96.43 and a twelve month high of $155.35. The stock has a market capitalization of $29.27 billion, a P/E ratio of 23.60, a PEG ratio of 2.88 and a beta of 1.19. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.20 and a quick ratio of 1.66.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.27 by $0.04. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. The firm had revenue of $1.68 billion during the quarter, compared to analysts' expectations of $1.67 billion. As a group, research analysts predict that Agilent Technologies, Inc. will post 5.55 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st will be paid a $0.248 dividend. This represents a $0.99 annualized dividend and a dividend yield of 0.97%. The ex-dividend date is Tuesday, April 1st. Agilent Technologies's dividend payout ratio is currently 22.76%.

Insider Transactions at Agilent Technologies

In related news, VP Rodney Gonsalves sold 1,908 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $121.98, for a total value of $232,737.84. Following the completion of the transaction, the vice president now directly owns 21,786 shares in the company, valued at approximately $2,657,456.28. This represents a 8.05 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Daniel K. Podolsky sold 1,819 shares of the firm's stock in a transaction on Monday, March 31st. The stock was sold at an average price of $116.46, for a total value of $211,840.74. Following the sale, the director now directly owns 35,737 shares of the company's stock, valued at approximately $4,161,931.02. This trade represents a 4.84 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,638 shares of company stock valued at $731,229.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.